Compare Lockheed Martin Corporation (LMT) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lockheed Martin Corporation vs Recursion Pharmaceuticals Inc — how do they compare? Lockheed Martin Corporation trades at $509.59 (market cap $117.22B), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: Lockheed Martin Corporation is far larger — about 54.8× Recursion Pharmaceuticals Inc's market cap, and Lockheed Martin Corporation pays a 2.72% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lockheed Martin Corporation for 86 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| LMT | RXRX | |
|---|---|---|
Market Cap | $117.22B | $2.14B |
Volume | 1,101,121 | 30,789,535 |
Sector | Industrials | Health |
52-Week High | $676.70 | $6.79 |
52-Week Low | $439.19 | $2.84 |
Typical Hold Time | 86 Days | 23 Days |
Enterprise Value | $133.96B | $1.66B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lockheed Martin (LMT) trades at $507.89, up 1.74% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported Q2 2026 EPS beat but missed in Q4 2025 and Q1 2026, with revenue growth from $71B in 2024 to $75B in 2025. Analyst consensus is strongly bullish with 59% buy ratings and a $635.33 price target, representing 25% upside. Recent news highlights dividend increases for 23 straight years and strategic AI partnerships through Skunk Works innovation.
LMT offers attractive valuation with P/E of 18.73 and strong defense contract backlog, though recent earnings misses and rising debt-to-asset ratio to 36.44% pose execution risks. The stock presents value opportunity amid sustained Pentagon spending, but investors should monitor contract performance and interest rate sensitivity given $19.63B long-term debt.
Recursion Pharmaceuticals (RXRX) trades at $3.95, down 7.49% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings miss after two consecutive beats, while maintaining negative profitability metrics with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche aim to expand the AI-driven drug discovery pipeline through 2028.
RXRX presents high-risk growth potential with strong analyst support (40% buy rating) but faces substantial financial challenges including persistent losses and negative cash flow from operations. The stock's investment case hinges on successful pipeline development and partnership monetization, though current valuation appears stretched at 37.14x sales given the lack of profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
